FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|November 20, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
Checkpoint Inhibitors in Cancer Care
Author(s)Jeffrey A. Sosman, MD
Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
Advertisement
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
In addition to other immunotherapies, Sosman says he is interested in
Articles in this issue
almost 13 years ago
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanomaalmost 13 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersalmost 13 years ago
Immunotherapy—An Increasingly Important Role in Oncologyalmost 13 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyalmost 13 years ago
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhDalmost 13 years ago
PD-1 and PD-L1 Antibodies in Lung Canceralmost 13 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadealmost 13 years ago
Nivolumab Plus Ipilimumab in Advanced Melanomaalmost 13 years ago
The Outlook for ImmunotherapiesAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5